PE20121585A1 - ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS - Google Patents
ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOSInfo
- Publication number
- PE20121585A1 PE20121585A1 PE2012000234A PE2012000234A PE20121585A1 PE 20121585 A1 PE20121585 A1 PE 20121585A1 PE 2012000234 A PE2012000234 A PE 2012000234A PE 2012000234 A PE2012000234 A PE 2012000234A PE 20121585 A1 PE20121585 A1 PE 20121585A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- ectodominium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23579909P | 2009-08-21 | 2009-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20121585A1 true PE20121585A1 (es) | 2012-11-29 |
Family
ID=43607614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000234A PE20121585A1 (es) | 2009-08-21 | 2010-08-23 | ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP2467164A2 (fr) |
JP (1) | JP5752687B2 (fr) |
KR (1) | KR20120059568A (fr) |
CN (1) | CN103002912A (fr) |
AU (1) | AU2010284018C1 (fr) |
BR (1) | BR112012003809A2 (fr) |
CA (1) | CA2771744A1 (fr) |
CR (1) | CR20120108A (fr) |
DO (1) | DOP2012000044A (fr) |
EA (1) | EA201200195A1 (fr) |
EC (1) | ECSP12011740A (fr) |
IL (1) | IL218097A0 (fr) |
IN (1) | IN2012DN01518A (fr) |
MA (1) | MA33582B1 (fr) |
MX (1) | MX336091B (fr) |
NI (1) | NI201200027A (fr) |
PE (1) | PE20121585A1 (fr) |
SG (1) | SG178509A1 (fr) |
TN (1) | TN2012000057A1 (fr) |
WO (1) | WO2011022727A2 (fr) |
ZA (1) | ZA201201195B (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2129396B1 (fr) | 2007-02-16 | 2013-08-21 | Merrimack Pharmaceuticals, Inc. | Anticorps contre erbb3 et leur utilisation |
DK3351558T3 (da) * | 2009-11-13 | 2020-06-02 | Daiichi Sankyo Europe Gmbh | Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme |
EP2516469B1 (fr) | 2009-12-22 | 2016-03-30 | Roche Glycart AG | Anticorps anti-HER3 et leurs utilisations |
CN102858335B (zh) | 2010-03-11 | 2015-04-15 | 梅里麦克制药股份有限公司 | Erbb3抑制剂在三阴性乳腺癌和基底样乳腺癌治疗中的用途 |
BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
KR102027011B1 (ko) | 2010-08-20 | 2019-09-30 | 노파르티스 아게 | 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
JP6033783B2 (ja) * | 2010-11-01 | 2016-11-30 | シムフォゲン・アクティーゼルスカブSymphogen A/S | Pan−her抗体組成物 |
US8476409B2 (en) | 2011-04-19 | 2013-07-02 | Merrimack Pharmaceuticals, Inc. | Bispecific anti-IGF-1R and anti-ErbB3 antibodies |
JPWO2012176779A1 (ja) * | 2011-06-20 | 2015-02-23 | 協和発酵キリン株式会社 | 抗erbB3抗体 |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
IN2014CN03042A (fr) | 2011-09-30 | 2015-07-03 | Regeneron Pharma | |
AU2012318541B2 (en) | 2011-10-06 | 2018-04-12 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
EP2788377B1 (fr) * | 2011-11-09 | 2019-01-23 | The UAB Research Foundation | Anticorps her3 et utilisations de ceux-ci |
EP3590538A1 (fr) | 2011-12-05 | 2020-01-08 | Novartis AG | Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3) |
WO2013124297A1 (fr) * | 2012-02-22 | 2013-08-29 | U3 Pharma Gmbh | Composition d'une protéine de liaison d'hb-egf et d'un inhibiteur de l'egfr |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
US20160232293A1 (en) * | 2013-10-17 | 2016-08-11 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
EP3087394A2 (fr) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies |
NZ724013A (en) * | 2014-02-28 | 2019-11-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
CN110642952B (zh) * | 2014-08-14 | 2021-05-25 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
WO2016038610A1 (fr) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions et procédés de traitement d'un cancer résistant à un inhibiteur de la tyrosine kinase (tki) |
WO2016038609A1 (fr) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anticorps anti-her3 et leurs utilisations |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
WO2017069628A2 (fr) | 2015-10-23 | 2017-04-27 | Merus N.V. | Molécules de liaison inhibant la croissance de cancer |
US11780925B2 (en) | 2017-03-31 | 2023-10-10 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene |
EP3665200A4 (fr) | 2017-08-09 | 2021-04-28 | University of Saskatchewan | Agents de liaison à her3 et utilisations associées |
BR112020002695A2 (pt) | 2017-08-09 | 2020-08-25 | Merus N.V. | anticorpos que se ligam à egfr e cmet |
GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
JP2021534811A (ja) * | 2018-06-22 | 2021-12-16 | シーアールディー ファーマシューティカルズ インコーポレイティド | 抗her3抗体およびその用途 |
AU2021360625A1 (en) * | 2020-10-14 | 2023-06-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof |
WO2023198138A1 (fr) * | 2022-04-13 | 2023-10-19 | 上海翰森生物医药科技有限公司 | Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2129396B1 (fr) * | 2007-02-16 | 2013-08-21 | Merrimack Pharmaceuticals, Inc. | Anticorps contre erbb3 et leur utilisation |
-
2010
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/fr active Application Filing
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 EP EP10810721A patent/EP2467164A2/fr not_active Withdrawn
- 2010-08-23 CA CA2771744A patent/CA2771744A1/fr not_active Abandoned
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Application Discontinuation
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2010284018C1 (en) | 2015-10-15 |
CR20120108A (es) | 2012-06-05 |
KR20120059568A (ko) | 2012-06-08 |
TN2012000057A1 (en) | 2013-09-19 |
ECSP12011740A (es) | 2013-02-28 |
CA2771744A1 (fr) | 2011-02-24 |
AU2010284018A1 (en) | 2012-03-22 |
ZA201201195B (en) | 2015-07-29 |
JP2013506622A (ja) | 2013-02-28 |
MX336091B (es) | 2016-01-08 |
SG178509A1 (en) | 2012-04-27 |
IN2012DN01518A (fr) | 2015-06-05 |
AU2010284018B2 (en) | 2014-06-05 |
CN103002912A (zh) | 2013-03-27 |
EA201200195A1 (ru) | 2012-12-28 |
DOP2012000044A (es) | 2012-06-30 |
WO2011022727A3 (fr) | 2013-06-27 |
IL218097A0 (en) | 2012-04-30 |
EP2467164A2 (fr) | 2012-06-27 |
WO2011022727A2 (fr) | 2011-02-24 |
MX2012002172A (es) | 2012-05-29 |
MA33582B1 (fr) | 2012-09-01 |
BR112012003809A2 (pt) | 2019-09-24 |
NI201200027A (es) | 2013-01-29 |
JP5752687B2 (ja) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20121585A1 (es) | ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS | |
AR087405A1 (es) | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek | |
AR077595A1 (es) | Tratamientos de combinacion | |
PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
AR091220A1 (es) | Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf | |
AR086579A1 (es) | Proteinas de union a antigeno | |
AR094849A1 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer | |
PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
EP3722810A3 (fr) | Profilage moléculaire de tumeurs | |
CL2014001282A1 (es) | Uso de un inmunoconjugado de un anticuerpo dirigido contra el receptor del factor de crecimiento epidérmico (egfr) para el tratamiento del cáncer resistente al tratamiento dirigido contra egfr, donde el inmunoconjugado es un anticuerpo enlazado a un agente citotóxico. | |
EA032934B1 (ru) | Применение комбинации, содержащей специфически распознающее cd38 антитело и циклофосфамид | |
NZ606195A (en) | Methods and compositions for liver cancer therapy | |
AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
BR112014024017A8 (pt) | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 | |
PE20161389A1 (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda | |
NZ592369A (en) | Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment | |
GB201114051D0 (en) | Compounds and their uses | |
PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
WO2011146568A8 (fr) | Prédiction de réponses à un inhibiteur de her | |
PE20170687A1 (es) | Proteinas de enlace a cd127 | |
EA201270124A1 (ru) | Новые терапевтические и диагностические средства | |
AR070821A1 (es) | Anticuerpo anti- tyrp1 (antitiroxina humana) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FX | Voluntary withdrawal |